Cancer library
Tips for getting through treatment with a radiotherapy mask
Bali, 19 June 2024, Bali International Hospital, a subsidiary of PT Pertamina Bina Medika Indonesia Healthcare Corporation (“IHC”), and Icon Asia Holdings Pte Ltd (“ICON”), a subsidiary of global cancer care provider Icon Group ̶ Australia’s largest provider of private cancer care services – has signed a Memorandum of Understanding (“MOU”) on 6 June, 2024 to enhance the quality of oncology care for the people of Indonesia.
The MOU was signed by dr. Dewi F. Fitriana, MPH, Chief Executive Officer of Bali International Hospital (“BIH”) and Ms. Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong, as part of a shared commitment to explore the provision of chemotherapy compounding, oncology pharmacy, expertise in medical oncology delivery and other oncology services at BIH.
“We recognise the urgent need to address the escalating cancer rates in Indonesia, where it stands as the second leading cause of death among non-communicable diseases,” stated dr. Dewi F. Fitriana, MPH. “Our partnership with Icon marks a crucial step towards bridging the gap in cancer care. Together, we are committed to delivering world-class oncology services that will significantly improve healthcare outcomes for the Indonesian population.”
With over 55 years of expertise in pharmaceuticals, extensive experience in chemotherapy compounding in Australia and New Zealand, and a proven track record in cancer treatment worldwide, Icon brings unparalleled insights to the development of a robust and sustainable oncology model for Indonesia and the wider region.
“At Icon, our mission is to deliver the best care possible, to as many people as possible, as close to home as possible. This MOU enables us to explore opportunities that will increase access to the best-in-class cancer care for Indonesians,” said Ms. Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong.
Advanced technology and equipment will underpin the BIH cancer care offering, including 3D-mammography, 3.0 Tesla MRI, 256-slice CT and a PET-CT to support cancer diagnostics. This will be combined with a Varian TrueBeam and SagiNova Brachytherapy to advance cancer treatment capability. This MOU will enable BIH to leverage Icon’s expertise in establishing world-class oncology services to enable best-in-class, patient-centred care at BIH.
BIH not only aims to improve the quality of healthcare in Indonesia, but also to make Indonesia a global health tourism destination. By combining health tourism and high-quality medicine, BIH is expected to attract tourists and patients from abroad to come to Indonesia.
Explore more from Icon
Discover our comprehensive collection of content designed to inform, support, and guide you through every aspect of cancer care. From the latest news and updates to personal patient experiences and educational resources, these materials provide valuable insights to help you better understand cancer, treatment options, and the journey ahead.
